<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363619</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01524</org_study_id>
    <nct_id>NCT04363619</nct_id>
  </id_info>
  <brief_title>Insights From the Retina on Cerebral Microvascular Dysfunction in Haemorrhagic Stroke</brief_title>
  <acronym>RETINA-ICH</acronym>
  <official_title>Insights From the Retina on Cerebral Microvascular Dysfunction in Haemorrhagic Stroke. A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fundoscopy, optical coherence tomography (OCT) and OCT-angiography (OCTA) are established&#xD;
      examinations and bear minimal risks. The recognition of retinal microvascular signs will&#xD;
      enhance the pathophysiological understanding of the vasculopathy in patients with&#xD;
      intracerebral haemorrhage (ICH) and aneurysmatic subarachnoid hemorrhage (aSAH) and might&#xD;
      serve as prognostic and diagnostic indicators.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to&#xD;
&#xD;
        -  To evaluate the feasibility of fundoscopy, OCT and OCTA imaging in the environment of a&#xD;
           Neurocritical Care Unit (NCCU)&#xD;
&#xD;
        -  To detect, quantify and associate microvascular changes in the retina with signs of&#xD;
           micro-vessel disease in ICH and DCI in aSAH&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>i. Number of fundus photography, OCT, and OCTA examinations with usable and quantifiable results.</measure>
    <time_frame>From hospital entry up to 3-6 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ICH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aSAH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OCT and OCTA</intervention_name>
    <description>Fundoscopy, OCT and OCTA will be performed 4 times in patients</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>ICH</arm_group_label>
    <arm_group_label>aSAH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All groups&#xD;
&#xD;
               -  Primary ICH or aSAH with symptoms onset &lt; 3 days&#xD;
&#xD;
               -  18 to unlimited years of age&#xD;
&#xD;
               -  Signed informed consent obtained from legal representative or patient ICH group&#xD;
&#xD;
               -  Primary ICH localized either in basal ganglia, thalamus, pons or cerebellum aSAH&#xD;
                  group&#xD;
&#xD;
               -  Ruptured aneurysm visualized in contrast-enhanced computed tomography (angio-CT),&#xD;
                  MRI or cerebral angiography Control group&#xD;
&#xD;
               -  Stroke due to perimesencepahlic subarachnoid hemorrhage, arteriovenous&#xD;
                  malformation or isolated traumatic brain injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All groups&#xD;
&#xD;
               -  Cerebral amyloid angiopathy or other neurodegenerative disease&#xD;
&#xD;
               -  History of migraine with aura or ischemic stroke&#xD;
&#xD;
               -  Contraindication for pupil dilation (intracranial hypertension, allergy against&#xD;
                  mydriatics, angle closure glaucoma)&#xD;
&#xD;
               -  Any pre-existing or manifest ocular condition affecting either the integrity of&#xD;
                  retinal vessels, transparency of optical media or the risk of acute angle closure&#xD;
                  glaucoma&#xD;
&#xD;
               -  Concomitant instable critical illness (e.g. sepsis, multi-organ failure)&#xD;
&#xD;
               -  Intracranial pressure &gt; 20mmHg and refractory to cerebrospinal fluid drainage&#xD;
&#xD;
               -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emanuela Keller, MD</last_name>
    <phone>+41442555671</phone>
    <email>emanuela.keller@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giselle Golby</last_name>
    <phone>+41442559891</phone>
    <email>giselle.golby@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela Keller, Prof MD</last_name>
      <phone>+41 44 255 56 71</phone>
      <email>Emanuela.Keller@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Giselle Golby</last_name>
      <phone>+41442559891</phone>
      <email>giselle.golby@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Emanuela Keller</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

